Literature DB >> 14627354

Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

A B R Thomson1, M Keelan, R Lastiwka, S Appelman-Eszczuk, L Zuk, L Drozdowski, A Prentice, P Sinclair.   

Abstract

The gastric pH-elevating effect of proton pump inhibitors such as omeprazole has been reported to be greater in the presence than in the absence of an H. pylori infection. It is unknown if this effect persists when a higher dose of omeprazole is taken. We undertook both 24-hr pH-metry and 24-hr aspiration studies in 12 H. pylori-positive patients with a history of duodenal ulcer (DU); (1) when not on omeprazole; (2) when on omeprazole 20 mg twice a day for 8 days; (3) two months after eradication of H. pylori and when not on omeprazole; and (4) after eradication of H. pylori and when on omeprazole twice a day. Eradication of H. pylori in DU results in lower mean and median pH; decreased percent pH > or = 3/ > or = 4, and greater median H+ after breakfast, after lunch, and overnight; and omeprazole appears to have less of a pH-elevating effect in the absence than in the presence of an H. pylori infection. The fall in gastric juice NH3 concentration as a result of eradicating H. pylori partially explained the lower pH-elevating effect of omeprazole. The variation in acid inhibitory effect of omeprazole after as compared with before eradication of H. pylori could not be explained by differences; (1) in gastric juice concentrations of IL-1alpha, IL-8, IL-13, or epidermal growth factor; (2) in the fasting or fed total concentration of gastric juice bile acids; (3) in the fasting concentrations or area under-the-curve (AUC) of the gastric H+ concentrations in response to food; or (4) in the pharmacokinetics of omeprazole. The difference in H+ AUC without omeprazole minus with omeprazole was actually greater when compared after versus before eradication of H. pylori. Thus, in DU the pH-elevating potency of omeprazole taken twice a day is greater in the presence than in the absence of an H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627354     DOI: 10.1023/a:1026147126821

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  65 in total

1.  Food coloring and monosodium glutamate: effects on the cephalic phase of gastric acid secretion and gastrin release in humans.

Authors:  M Goldschmiedt; J S Redfern; M Feldman
Journal:  Am J Clin Nutr       Date:  1990-05       Impact factor: 7.045

2.  Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin.

Authors:  A W Harris; P A Gummett; J J Misiewicz; J H Baron
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

3.  Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients.

Authors:  P Gionchetti; D Vaira; M Campieri; J Holton; M Menegatti; A Belluzzi; E Bertinelli; M Ferretti; C Brignola; M Miglioli
Journal:  Am J Gastroenterol       Date:  1994-06       Impact factor: 10.864

4.  Helicobacter pylori infection induces a decrease in immunoreactive-somatostatin concentrations of human stomach.

Authors:  H Kaneko; K Nakada; T Mitsuma; K Uchida; A Furusawa; Y Maeda; K Morise
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

5.  Gastrin and somatostatin in Helicobacter pylori infected antral mucosa.

Authors:  L Odum; H D Petersen; I B Andersen; B F Hansen; J F Rehfeld
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

6.  Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole.

Authors:  E F Verdú; D Armstrong; J P Idström; J Labenz; M Stolte; G Dorta; G Börsch; A L Blum
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

7.  Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer.

Authors:  J Labenz; B Tillenburg; U Peitz; J P Idström; E F Verdú; M Stolte; G Börsch; A L Blum
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

Review 8.  Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease.

Authors:  J E Crabtree; I J Lindley
Journal:  Eur J Gastroenterol Hepatol       Date:  1994-12       Impact factor: 2.566

9.  Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying.

Authors:  A Robert; A S Olafsson; C Lancaster; W R Zhang
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

10.  Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease.

Authors:  E M el-Omar; I D Penman; J E Ardill; R S Chittajallu; C Howie; K E McColl
Journal:  Gastroenterology       Date:  1995-09       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.